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Background: Nanobiotechnology can provide more efficient tools for diagnosis, targeted and 
personalized therapy, and increase the chances of brain tumor treatment being successful. Use 
of nanoparticles is a promising strategy for overcoming the blood–brain barrier and delivering 
drugs to the brain. Gelatin-siloxane (GS) nanoparticles modified with Tat peptide can enhance 
plasmid DNA transfection efficiency compared with a commercial reagent.
Methods: SynB-PEG-GS nanoparticles are membrane-penetrable, and can cross the blood–
brain barrier and deliver a drug to its target site in the brain. The efficiency of delivery was 
investigated in vivo and in vitro using brain capillary endothelial cells, a cocultured blood–brain 
barrier model, and a normal mouse model.
Results: Our study demonstrated that both SynB-PEG-GS and PEG-GS nanoparticles had 
a spherical shape and an average diameter of 150–200 nm. It was shown by MTT assay that 
SynB-PEG-GS nanoparticles had good biocompatibility with brain capillary endothelial cells. 
Cellular uptake by SynB-PEG-GS nanoparticles was higher than that for PEG-GS nanoparticles 
for all incubation periods. The amount of SynB-PEG-GS nanoparticles crossing the cocultured 
blood–brain barrier model was significantly higher than that of PEG-GS nanoparticles at all 
time points measured (P , 0.05). In animal testing, SynB-PEG-GS nanoparticle levels in the 
brain were significantly higher than those of PEG-GS nanoparticles at all time points measured 
(P , 0.01). In contrast with localization in the brain, PEG-GS nanoparticle levels were signifi-
cantly higher than those of SynB-PEG-GS nanoparticles (P , 0.01) in the liver.
Conclusion: This study indicates that SynB-PEG-GS nanoparticles have favorable properties 
with regard to morphology, size distribution, and toxicity. Moreover, the SynB-PEG-GS nano-
particles exhibited more efficient brain capillary endothelial cell uptake and improved crossing 
of the blood–brain barrier. Further, biodistribution studies of rhodamine-loaded nanoparticles 
demonstrated that modification with the SynB peptide could not only improve the ability of 
PEG-GS nanoparticles to evade capture in the reticuloendothelial system but also enhance their 
efficiency in crossing the blood–brain barrier.
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Introduction
The blood–brain barrier is a complex physiological checkpoint in the central nervous 
system that inhibits free diffusion of circulating molecules from the blood into the 
brain. Many brain diseases cannot be treated due to the presence of barriers in the 
brain. Therefore, development of a novel drug delivery system which would signifi-
cantly enhance the delivery of therapeutic agents across the blood–brain barrier holds 
the key to treatment of a number of brain diseases and is an impending mission for 
research workers.
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In recent years, various strategies have been proposed 
to circumvent the blood–brain barrier. Nanobiotechnology 
will provide more efficient tools for diagnosis, targeted 
personalized therapy, and increase the chances of curative 
treatment for brain tumors.1 The use of nanoparticles repre-
sents a promising strategy for overcoming the blood–brain 
barrier.2 Nanoparticle systems are increasingly demonstrating 
an advantage in effective transportation of various drugs, 
including temozolomide,3 loperamide,4 and doxorubicin,5 
which are not normally able to penetrate the blood–brain 
  barrier. Further, due to their small size and appropriate sur-
face functionalization, nanoparticles can flow easily through 
blood capillaries and enter target cancer cells.6,7
Using appropriate surface modification, nanoparticle 
carriers have been shown to have good cellular uptake and 
low cytotoxicity in vitro and in vivo. Methods for surface 
modification of nanoparticles have been developed and 
include decoration with poly(ethylene glycol) (PEG),8,9 
polysorbate-80,3 monoclonal antibody, and cationic cell-
penetrating peptides.10 Recently, nanoparticles with multiple 
modifications for delivery in the central nervous system 
have been constructed by a number of research groups. 
These include lactoferrin-conjugated polyethylene glycol-
polylactide-polyglycolide (PEG-PLGA) nanoparticles11 and 
a leptin-derived 30 amino acid peptide-modified pegylated 
poly-L-lysine dendrigraft.12
Nanoparticles coated with PEG show potential for use 
as potent drug carriers because they are able to evade the 
reticuloendothelial system and circulate in the blood for a 
long period of time.13,14 Gao et al15 and Lu et al16 reported a 
poly(lactic acid) nanoparticle system via PEG and targeted 
molecular modification. They demonstrated increased uptake 
of these nanoparticles by brain capillary endothelial cells. In 
an in vivo experiment, there was higher localized nanoparticle 
accumulation in the brain and a 2.98-fold increase in the area 
under the concentration-time curve over 24 hours compared 
with controls not exposed to the modified nanoparticles.
Cationic cell-penetrating peptide-mediated endocytosis 
is one of the mechanisms by which drug carriers cross the 
blood–brain barrier. Cell-penetrating peptides are a group 
of short peptides with a potent ability to penetrate the 
blood–brain barrier, and have been investigated extensively 
in recent decades and found to be materials well suited for 
development as drug delivery vehicles. The advantages of 
peptides include their relatively small molecular weight, ease 
of synthesis, relatively low cytotoxicity and immunogenicity, 
and degradation in vivo to naturally occurring compounds.17,18 
The SynB peptides (RGGRLSYSRRRFSTSTGR) are a 
  family of cell-penetrating peptides that show   charge-mediated 
  blood–brain barrier selectivity occurring via a caveolae-
independent pathway.19 Furthermore, intracellular delivery 
of SynB   peptides has been used extensively in cationic 
cell-penetrating peptide vector-mediated strategies which 
enable passage of a large variety of small molecules as well 
as proteins across cell membranes in vitro and across the 
blood–brain barrier in vivo.20,21
The aim of our study was to confirm whether SynB-
PEG nanoparticles decorated with gelatin-siloxane (SynB-
PEG-GS) could traverse the blood–brain barrier from the 
systemic circulation and increase the dose of drug reaching 
the brain in vivo and in vitro. In this study, a micellar brain 
delivery system was constructed by conjugating SynB-PEG 
with gelatin-siloxane nanoparticles. Its properties, including 
structure, morphology, and size distribution, were evaluated. 
Further, the toxicity of SynB-PEG-GS nanoparticles was 
assessed by MTT assay using brain capillary endothelial 
cells. In addition, the efficiency of transport of SynB-
PEG-GS nanoparticles across brain capillary endothelial 
cells was investigated in vivo and in vitro, using a coculture 
blood–brain barrier model and a normal mouse model, 
respectively.
Materials and methods
Materials and animals
Gelatin (bloom number 240-270, pH 4.5–5.5) was purchased 
from BBI (Madison, WI). 3-Glycidoxypropyl-trimethoxysi-
lane (GPSM) and 3-aminopropyl-trimethoxysilane (APTMS) 
were purchased from Acros Organics (Fair Lawn, NJ). 
N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) was 
purchased from Pierce Biotechnology Inc (Rockford, IL). 
1-[3-(dimethylamino) propyl]-3-ethylcarbodiimide (EDC) and 
N-Hydroxysuccinimide (NHS) were provided by Chinese GL 
Biochem Ltd, (Shanghai, China). NH2-PEG-COOH was pro-
vided by Chinese Beijing Kaizheng Biotech Development Co, 
(Beijing, China). N-pys-activated C-terminal Cys containing 
SynB peptide (RGGRLSYSRRRFSTSTGR) and rhodamine 
(TAMRA)-labeled SynB peptide were provided by Chinese 
Peptide Co, (Hangzhou, China). All materials used were of 
analytical grade and used without further purification.
Adult nude mice (6 weeks old, 18–20 g, on a Balb/c 
nu/nu background) and Sprague-Dawley rats (3 weeks old) 
were obtained from the laboratory animal center of X  iamen 
University. The animals used for the experiment were 
treated according to the protocols evaluated and approved 
by the Chinese National Science and Technology Com  mittee 
guidelines.
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Preparation of nanoparticles
Amino-functionalized gelatin-siloxane nanoparticles were 
prepared according to previously reported methods.22 
Briefly, 0.2 g of GPSM was added to 1% gelatin solution in 
HCl (pH 3.0) at 40°C under stirring for 20 minutes, and the 
mixture was then continuously stirred for another 30 minutes 
at 60°C. Generation of gelatin-siloxane nanoparticles was 
associated with the introduction of APTMS into the above 
mixture. The resulting gelatin-siloxane nanoparticles were 
purified by centrifugation (14,000 rpm, 25°C, 20 minutes) 
three times. We conjugated rhodamine B isothiocyanate dye 
(RITC) to the surfaces of gelatin-siloxane nanoparticles using 
the reaction between the isothiocyanate group of RITC and 
the primary amino group of gelatin-siloxane nanoparticles. 
Then, 0.3 mg of RITC was added to 50 mg of gelatin-siloxane 
nanoparticles in pH 8.0 phosphate-buffered solution and 
incubated in a rotator for 2 hours at room temperature. After 
purification by centrifugation, PEG was linked to the gelatin-
siloxane nanoparticle surfaces using EDC and NHS as cou-
pling reagents. The sulfhydryl group was then introduced to 
the surface of PEGylated gelatin-siloxane nanoparticles via 
SPDP. SynB peptide with a free sulfhydryl group at the end 
of the strand was subsequently coupled to the nanoparticles 
via a disulfide bond. SynB-PEG-GS nanoparticles were 
finally obtained by centrifugation for 20 minutes at 25°C and 
19,000 rpm, and washed three times with deionized water.
Cell cultures
Primary cultures of rat brain capillary endothelial cells were 
obtained from 3-week-old Sprague-Dawley rats, as previ-
ously described.23 First, gray matter isolated from rat brain 
was put into a glass homogenizer for homogenizing, then 
passed through a cell filter (150 µm, 75 µm) and digested 
with collagenase type 2 (1 mg/mL) in a shaker for one hour 
at 37°C. The cell suspension was separated by centrifuga-
tion in 20% bovine serum albumin-endothelial cell medium 
(1000 × g for 20 minutes). Next, the brain capillary endothe-
lial cells were collected and washed twice in endothelial cell 
medium before plating on 35 mm plastic dishes coated with 
collagen type IV 0.1 mg/mL (ScienCell, Carlsbad, CA). 
Brain capillary endothelial cell cultures were maintained in 
endothelial cell medium supplemented with 1% endothelial 
cell growth supplement (ScienCell), 5% fetal bovine serum 
(ScienCell), and 1% penicillin/streptomycin (ScienCell) at 
37°C in a humidified atmosphere of 5% CO2/95% O2. On the 
third day, the old medium were replaced in the cell culture 
dishes. When the cell cultures reached 80% confluence, the 
purified endothelial cells were digested with trypsin solution 
(0.125%, w/v), checked by immunostaining for endothelial 
cell factor VIII (Beijing Biosynthesis Biotechnology Co, 
Ltd, China), and used to construct in vitro blood–brain bar-
rier models.
Cerebral astrocytes were obtained from neonatal Sprague-
Dawley rats. Cortical brain tissue pieces were removed from 
the brain and mechanically dissociated in astrocyte culture 
medium (Dulbecco’s Modified Eagle’s Medium supple-
mented with 10% fetal bovine serum, 10% calf serum, and 
1% penicillin/streptomycin). Cells were seeded into cell 
culture flasks at 37°C with a humidified atmosphere of 5% 
CO2/95% O2. When cultures reached approximately 80% 
confluence, flasks with confluent cultures were shaken at 
37°C (200 rpm, 12 hours) in order to obtain type 1 astrocytes. 
The purity of the astrocytes was checked by immunostaining 
for glial fibrillary acidic protein (Beijing Biosynthesis Bio-
technology Co, Ltd,), and the cells were used for constructing 
in vitro blood–brain barrier models.
Construction of cocultured  
blood–brain barrier models
Astrocytes (1.5 × 105 cells/mL) were seeded on the bottom 
side of the polyester membrane of a Transwell insert (Corning, 
New York, NY), and the Transwell insert was placed in 6-well 
culture plates in the opposite direction of bottom-top. After 
culture for 24 hours, endothelial cells (1.6 × 105 cells/mL) 
were seeded on the inside of the Transwell insert, and the 
Transwell insert was placed in 12-well culture plates. These 
cells were cultured in endothelial cell medium (ScienCell) 
supplemented with 1% endothelial cell growth supple-
ment (ScienCell), 5% fetal bovine serum (ScienCell), and 
1% penicillin/streptomycin (ScienCell) at 37°C and 5% 
CO2/95% O2 saturated humidity. The endothelial cell medium 
was changed every 3 days. The cocultured cells were grown 
for 14 days to confluence before experiment.
Immunofluorescent staining
In order to determine the brain endothelial tight junction 
proteins for various blood–brain barrier models, a cocultured 
blood–brain barrier model was stained with claudin-5. The in 
vitro blood–brain barrier model was washed with phosphate-
buffered solution and fixed with 4% polyphosphate formal-
dehyde solution for 20 minutes at room temperature. The 
blood–brain barrier model was then blocked with 10% rabbit 
serum for 30 minutes and incubated with rabbit anticlaudin-5 
(1:50, Santa Cruz) for 2 hours at 37°C. Next, these samples 
were incubated with TRITC-labeled antirabbit IgG (Beijing 
CoWin Bioscience Co, Ltd, Beijing, China) for one hour 
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at 37°C. For nuclear staining, the cells were incubated with 
4.6-diamidino-2-phenylindole (DAPI, 1:500; Roche, Basel, 
Switzerland) for 15 minutes at room temperature. Finally, 
the blood–brain barrier model was washed three times 
with phosphate-buffered solution and sealed pieces were 
examined by confocal laser scanning microscopy (FV 1000, 
Olympus, Shinjuku-ku, Japan).
Characterization of nanoparticles
Observation of gelatin-siloxane, PEG-GS, and SynB-PEG-GS 
nanoparticles was carried out using transmission electron 
microscopy (2100 HC, Japan) at an operating voltage of 
200 kV in bright-field mode. Dilute suspensions of nano-
particles in water were dropped onto a copper grid and then 
air-dried for analysis by transmission electron microscopy. The 
mean diameter and zeta potential of the nanoparticles were 
measured using a Nano-ZS zetasizer dynamic light scattering 
detector (Malvern Instruments, Worcestershire, UK). Each 
experiment was conducted 22 times for reproducibility.
MTT assay
Brain capillary endothelial cells were cultured in endothelial 
cell medium supplemented with 5% fetal bovine serum, 
1% endothelial cell growth supplement, and 1% penicil-
lin/streptomycin at 37°C, with 5% CO2/95% O2 saturated 
humidity. Brain capillary endothelial cells were seeded into 
96-well plates at a density of 5 × 103 cells/well and incubated 
at 37°C with 5% CO2 for 24 hours to allow cell attachment. 
PEG-GS and SynB-PEG-GS nanoparticles were diluted 
with 100 µL of serum-free endothelial cell medium to dif-
ferent concentrations (100–600 µg/mL) and incubated with 
brain capillary endothelial cells, with cells not exposed to 
nanoparticles serving as controls. After 4 and 12 hours of 
coincubation, the medium was removed and the cells were 
washed with phosphate-buffered solution. The fresh com-
plete culture medium containing 20 µL of MTT solution 
(5 mg/mL in phosphate-buffered solution) was cultured for a 
further 4 hours. The MTT solution was removed and 100 µL 
of dimethylsulfoxide was added (at 37°C for 30 minutes) to 
dissolve the formazan crystals that had formed. Cell viability 
was evaluated at 570 nm in a spectrophotometric microplate 
reader (Bio-tek ELX800, Winooski, VT). Each experiment 
was repeated five times, and the relative cell viability (%) was 
expressed as a percentage in comparison with control cells.
Cellular uptake of nanoparticles
For the study of nanoparticle uptake by brain capillary 
endothelial cells, PEG-GS and SynB-PEG-GS nanoparticles 
were incubated with confluent monolayers of brain capillary 
endothelial cells (100 µg nanoparticles/105 cells/well) in 
serum-free endothelial cell medium at 37°C for different time 
periods (2, 4, and 6 hours). After incubation, the cells were 
collected, centrifuged, and resuspended in 300 µL of 70% 
nitric acid and incubated at 200°C for 15 minutes, after which 
the cells were diluted 100× in distilled water for assay by 
inductively coupled plasma mass spectrometry. All samples 
were run in quadruplicate and the data show the average of 
four measurements.
Model of nanoparticle transport across 
blood–brain barrier
When the in vitro blood–brain barrier model was constructed, 
cells were grown for 14 days to confluence. On the day of 
the experiment, the cells were rinsed twice with serum-free 
endothelial cell medium. The medium was then added into the 
apical chamber at a concentration of 100 µg/mL for PEG-GS 
and SynB-PEG-GS nanoparticles. In the control wells, the 
same medium was added but without nanoparticles. A 1 mL 
volume of sample medium was taken from the basolateral 
compartment at 5, 10, 20, 40, and 80 minutes, and detected by 
inductively coupled plasma mass spectrometry. All samples 
were run five times and the data show the average of five 
measurements.
Animal testing
For the animal experiments, a total of 21 congenitally athy-
mic nude male mice (6 weeks old, body weight 18–20 g, 
on Balb/c nu/nu background, laboratory animal center of 
  Xiamen   University, China) were randomly divided into three 
groups of seven mice each. Rhodamine-loaded PEG-GS 
nanoparticles and SynB-PEG-GS nanoparticles were pre-
pared using physiological saline solution. The nanoparticle 
formulations were injected into the tail veins of nude mice 
(1 mL, 60 mg/kg). At 0.5, 1, 2, and 4 hours following injec-
tion, the mice were anesthetized using 10% chloral hydrate 
(0.6 mL/kg) and images were taken using the Maestro in vivo 
imaging system (CRI Inc, Hopkinton, MA). In order to ana-
lyze the quantitative distribution of the nanoparticles in vivo, 
the mice were sacrificed at 0.5, 2, 4, 6, 12, and 24 hours after 
injection. The brains and livers were collected immediately, 
washed twice with physiological saline solution, and also 
visualized using the Maestro in vivo imaging system. The 
fluorescence signal intensity was quantified as the sum of 
all detected photon counts per second within the region of 
interest after subtracting the background luminescence and 
presented as total signal counts/scaled/second.
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Statistical analysis
All statistical analyses were performed using SPSS 
13.0 (SPSS Inc, Chicago, IL). Data were reported as the 
mean ± standard deviation. Student’s t-test was used for 
comparisons between the treatment groups and control 
group. P values ,0.05 were considered to be statistically 
significant.
Results
Characterization of nanoparticles
The theoretical structure of the SynB-PEG-GS nanoparticles is 
shown in Figure 1. Gelatin-siloxane nanoparticles were prepared 
using GPSM and gelatin solution. Rhodamine B isothiocyanate 
dye was conjugated to the gelatin-siloxane nanoparticles via 
its primary amino group. NH2-PEG-COOH was linked to the 
gelatin-siloxane nanoparticle surfaces using EDC and NHS as 
coupling reagents. SPDP was used to conjugate PEG via NHS. 
Finally, sulfhydryl-containing SynB peptide (RGGRLSYSR-
RRFSTSTGR) was attached to this linker via a disulfide bond, 
which was from the SynB-PEG-GS nanoparticles.
Transmission electron microscopy showed that the SynB-
PEG-GS and PEG-GS nanoparticles were both spherical, and 
the average size of the various types of nanoparticles was 
150–200 nm (Figure 2). Dynamic light scattering analysis 
was used to measure the size of the gelatin-siloxane, PEG-GS, 
and SynB-PEG-GS nanoparticles (Table 1). The particle sizes 
of gelatin-siloxane, PEG-GS, and SynB-PEG-GS nanopar-
ticles were 180.73 ± 11.57 nm, 182.91 ± 10.30 nm, and 
194.55 ± 6.43 nm, respectively. Zeta potential measu  rement 
showed the charge values of gelatin-siloxane, PEG-GS, 
and SynB-PEG-GS nanoparticles to be 28.50 ± 3.33 mV , 
2.50 ± 1.97 mV , and 31.82 ± 3.11 mV , respectively.
Immunofluorescent staining
Brain capillary endothelial cells and astrocytes were isolated 
from the rat brain and grown in nonoverlapping continuous 
monolayers, and demonstrated to have an elongated, fusiform 
morphology and positive immunostaining for endothelial cell 
factor VIII (Figure 3A). The astrocytes were polygonal with 
long podocytic cell processes and immunostained positive for 
glial fibrillary acidic protein (Figure 3B). Immunostaining with 
claudin-5 was performed using the blood–brain barrier model of 
brain capillary endothelial cells and astrocytes cocultured under 
previously described conditions after 17 days (Figure 3C). 
High staining of claudin-5 was observed in the samples, and 
tight junction proteins in the blood–brain barrier model were 
strongly expressed in the vicinity of the cell borders.
MTT assay
The result of the MTT viability assay is shown in Figure 4. 
The viability of brain capillary endothelial cells treated with 
SynB-PEG-GS nanoparticles (100–600 µg/mL) for 4 hours was 
over 80.51%. In addition, the viability of cells pretreated with 
SynB-PEG-GS nanoparticles for 12 hours was 78.22%,70.60%, 
and 62.70% at a nanoparticle concentration of ,400 µg/mL, 
500 µg/mL, and 600 µg/mL, respectively. Viability of cells 
pretreated with PEG-GS nanoparticles (100–600 µg/mL) for 
4 hours was 79.44%. Even in brain c  apillary endothelial cells 
incubated for 12 hours with PEG-GS nanoparticles (600 µg/mL), 
viability was still 70.00%. There was no significant difference 
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Figure 1 Synthesis of gelatin-siloxane nanoparticles coated with PEg and SynB peptide.
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in the to  xicity of the different formulations at the same con-
centrations (P . 0.05) at any incubation time.
Uptake of nanoparticles by brain capillary 
endothelial cells
Figure 5 shows significant uptake of SynB-PEG-GS nano-
particles by brain capillary endothelial cells, as compared 
with PEG-GS nanoparticles which showed relatively poor 
uptake. Cells treated with PEG-GS nanoparticles were dem-
onstrated to have negligible uptake, while those treated with 
SynB-PEG-GS nanoparticles showed substantial uptake. In 
addition, after a 4-hour incubation period, the cellular uptake 
index of SynB-PEG-GS nanoparticles was 1.29-fold higher 
than that of PEG-GS nanoparticles, and this difference was 
statistically significant (P , 0.05).
Cell monolayer permeation studies
A cocultured blood–brain barrier model confirmed by 
claudin-5 immunostaining was used to study the delivery 
of various nanoparticles to the brain in vitro. The results of 
SynB-PEG-GS and PEG-GS nanoparticle transport studies 
are shown in Figure 6. The amount of nanoparticles crossing 
the cocultured blood–brain barrier model showed a time-
dependent pattern. Moreover, the passage of SynB-PEG-GS 
nanoparticles across the blood–brain barrier was significantly 
greater than that of PEG-GS nanoparticles at the different 
time points (P , 0.05). After an 80-minute incubation period, 
the quantity of SynB-PEG-GS nanoparticles that permeated 
across the blood–brain barrier was 1.99-fold higher than that 
of PEG-GS nanoparticles.
Animal experiments
In order to demonstrate delivery of the SynB-PEG-GS nano-
particles to the mouse brain, a series of in vivo fluorescence 
imaging system experiments was performed. Figure 7 shows 
the real-time in vivo biodistribution and excretion profile 
for SynB-PEG-GS nanoparticles in a living mouse. For 
the entire duration of the experiment, strong fluorescence 
signals were observed in the brains of mice treated with 
SynB-PEG-GS nanoparticles. In the first 30 minutes, there 
was no definite fluorescence signal from nanoparticles in 
the brain. The fluorescence signal in the brain area was 
enhanced one hour following injection and reached its 
highest levels 2 hours after treatment, and had receded by 
4 hours after injection. However, there was no obvious 
fluorescence signal in the brain areas of mice treated with 
PEG-GS nanoparticles.
Quantitative analysis of rhodamine B isothiocyanate-
labeled nanoparticle biodistribution following intravenous 
administration to the tail is shown in Figure 8. As indicated 
in Figure 8A, the total fluorescent signals excited by SynB-
PEG-GS and PEG-GS nanoparticles both reached a maximal 
level in the brain 2 hours after injection. At 24 hours after 
Figure 2 Transmission electron microscopic images of (A) SynB-PEg nanoparticles decorated with gelatin-siloxane, and (B) PEg-gelatin-siloxane nanoparticles.
Table 1 Physical characterization of various types of nanoparticles 
(n = 22)
Formulation Particle size  
(nm)
Zeta potential 
(mV)
DLS TEM
gS NPs 180.73 ± 11.57 174.73 ± 11.75 28.50 ± 3.33
PEg-gS NPs 182.91 ± 10.30 174.05 ± 11.36   2.50 ± 1.97
SynB-PEg-gS NPs 194.55 ± 6.43 186.00 ± 8.04 31.82 ± 3.11
Abbreviations: DLS, dynamic light scattering; gS, gelatin-siloxane; SynB-PEg-gS, 
SynB-PEg  nanoparticles  decorated  with  gelatin-siloxane;  PEg-gS,  PEg-gelatin-
siloxane nanoparticles; NPs, nanoparticles; TEM, transmission electron microscopy.
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injection, the fluorescent signals had faded. In addition, 
SynB-PEG-GS nanoparticles were present in significantly 
higher numbers than were PEG-GS nanoparticles at all 
time points (P , 0.01). In contrast with brain localization, 
the total fluorescent signals of various nanoparticles in the 
liver reached a maximal level at 4 hours after injection and 
PEG-GS nanoparticle levels were significantly higher than 
those of SynB-PEG-GS nanoparticles (P , 0.01) at the dif-
ferent time points, as shown in Figure 8B.
Discussion
In this study, a novel nanoparticle for drug delivery to the 
brain was synthesized by decorating SynB-PEG with gelatin-
siloxane. The basic properties of nanoparticles, such as diam-
eter and zeta potential, play an important role for longevity in 
the blood and for crossing the blood–brain barrier. Generally, 
the size of nanoparticles for delivery to the brain needs to 
be under 200 nm to enable endocytosis by brain capillary 
cells. Our study demonstrates that both SynB-PEG-GS and 
PEG-GS nanoparticles had a spherical shape and a mean 
diameter of 150–200 nm (Figure 2). Therefore, modification 
of the SynB peptide did not affect the shape of the PEG-GS 
nanoparticles. As shown in Table 1, all of the nanoparticles 
had an average diameter of 170–190 nm. However, the mean 
diameter of the nanoparticles detected by dynamic light scat-
tering analysis was higher than that detected by transmission 
electron microscopy, which might be due to hydration of the 
PEG associated with the nanoparticles.24 The modification 
of gelatin-siloxane nanoparticles with PEG could result 
in a decrease in the zeta potential to a nearly neutral level 
(2.50 ± 1.97 mV). With further attachment of the positively 
charged SynB peptide, the zeta potential value increased to 
31.82 ± 3.11 mV , which makes it possible to deliver plasmid 
Figure 3 Characterization of cells and blood–brain barrier model by immunofluorescent staining.
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DNA to the brain without compromising the blood–brain 
barrier.25 These cationic nanoparticles are thus likely to bind 
to the anionic luminal plasma membrane, and subsequently 
become internalized into cells via endocytosis.26
The ability of these nanoparticles to cross the blood–brain 
barrier was investigated using an in vitro cocultured model 
consisting of primary rat brain capillary endothelial cells and 
astrocytes. In our study, brain capillary endothelial cells and 
astrocytes were isolated from 3-week-old Sprague-Dawley 
rats. To determine whether these cells were brain capillary 
endothelial cells or astrocytes, respectively, we measured 
endothelial cell factor VIII and glial fibrillary acidic protein 
by immunofluorescence. As shown in Figure 3, the brain 
capillary endothelial cells showed elongated, fusiform 
morphology and positive immunostaining for factor VIII 
(Figure 3A). The astrocytes characterized were polygonal 
and showed positive immunostaining for glial fibrillary acidic 
protein (Figure 3B). Claudin-5 immunofluorescence was 
performed for the blood–brain barrier model of cocultured 
brain capillary endothelial cells and astrocytes, as shown in 
Figure 3C. In the blood–brain barrier model, the tight junction 
protein, claudin-5, was strongly expressed in the vicinity of 
cell borders, and as clear and smooth lines.
Evaluation of the toxicity of nanocomplexes on cells 
in culture is crucial to their eventual use in biomedical 
applications. We used a MTT cell viability assay to evalu-
ate whether the prepared nanoparticles were toxic to brain 
capillary endothelial cells. Formazan absorbance indicated 
that the brain capillary endothelial cells seeded onto the dif-
ferent membranes were able to convert the MTT into a blue 
formazan product.   Treatment of brain capillary endothelial 
cells with nanoparticles carrying the different modifications 
for 4 hours and 12 hours decreased cell viability in a time-
dependent and concentration-dependent manner (Figure 4). 
Viability was over 80.51% in brain capillary endothelial cells 
treated with   SynB-PEG-GS nanoparticles (100–600 µg/mL) 
for 4 hours. Even after incubation for 12 hours, the viability 
of brain   capillary endothelial cells was 78.22%, 70.60%, 
and 62.70% at nanoparticle concentrations ,400 µg/mL, 
500 µg/mL, and 600 µg/mL, respectively. In addition, the 
viability of cells pretreated with PEG-GS nanoparticles 
(100–600 µg/mL) for 4 hours was over 79.44%. Even in brain 
capillary endothelial cells incubated for 12 hours with PEG-
GS nanoparticles (600 µg/mL), viability was still 70.00%. At 
the same time point of incubation, there was no significant 
difference in the toxicity of the different formulations at any 
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barrier model detected by inductively coupled plasma mass spectrometry. 
Notes:  **P  ,  0.01  and  *P  ,  0.05  indicate  a  statistically  significant  difference; 
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Figure 7 Dynamic imaging of nude mice administered rhodamine B isothiocyanate-
labeled nanoparticles. Mice without injection were located in the left for each group.
Abbreviations:  SynB-PEg-gS,  SynB-PEg  nanoparticles  decorated  with  gelatin-
siloxane; PEg-gS, PEg-gelatin-siloxane nanoparticles.
0
10
20
30
40
50
60
70
80
90
100
Time (h)
N
a
n
o
p
a
r
t
i
c
l
e
s
 
u
p
t
a
k
e
(
µ
g
/
1
0
5
 
c
e
l
l
s
/
w
e
l
l
)
 
PEG-GS
SynB-PEG-GS
*
6  4  2 
Figure  5  Amounts  of  SynB-PEg-gS  and  PEg-gS  taken  up  by  brain  capillary 
endothelial cells detected by inductively coupled plasma mass spectrometry. 
Notes: P , 0.05 indicates a statistically significant difference; means ± standard 
deviations are indicated (n = 4).
Abbreviations:  SynB-PEg-gS,  SynB-PEg  nanoparticles  decorated  with  gelatin-
siloxane; PEg-gS, PEg-gelatin-siloxane nanoparticles.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1038
Tian et alInternational Journal of Nanomedicine 2012:7
of the given concentrations (P . 0.05). These results indicate 
that the SynB-PEG-GS nanoparticles were nontoxic and had 
good biocompatibility, and there may be two reasons for this 
observation. First, gelatin and GPSM, the materials used 
in the construction of the various nanoparticles, had good 
compatibility, as we have previously reported.22 Second, the 
toxicity of the PEG component has also been reported to be 
acceptably low.27
To determine whether nanoparticles decorated by 
the SynB peptide were internalized into brain capillary 
endothelial cells, the cellular uptake of SynB-PEG-GS and 
PEG-GS nanoparticles by brain capillary endothelial cells 
was evaluated for the different time intervals using induc-
tively coupled plasma mass spectrometry. As indicated in 
Figure 5, the   cellular uptake of SynB-PEG-GS nanopar-
ticles was higher than that of PEG-GS nanoparticles for all 
incubation times. In particular, the value for SynB-PEG-GS 
nanoparticles was 1.29-fold higher than that for PEG-GS 
nanoparticles after a 4-hour incubation period. To investigate 
this further, a cocultured blood–brain barrier model was used 
to test the ability of the various nanoparticles to cross the 
blood–brain barrier in vitro. The amount of nanoparticles 
which crossed in the cocultured blood–brain barrier model 
showed a   time-dependent pattern (Figure 6). Moreover, 
SynB-PEG-GS nanoparticle levels were significantly higher 
than those of PEG-GS nanoparticles at various time points 
(P , 0.05). After an 80-minute incubation period, the quan-
tity of   SynB-PEG-GS nanoparticles that had permeated 
was   1.99-fold greater than that of PEG-GS nanoparticles. 
The results of the in vitro study showed that PEG-GS 
nanoparticles decorated with SynB peptide did improve the 
ability of the nanoparticles to cross the blood–brain bar-
rier. SynB peptide is from a new family of cell-penetrating 
peptides, an 18 amino acid peptide originally isolated from 
porcine leukocytes, which does not require receptors or an 
energy-dependent pathway to penetrate the membrane.28 
As a sequence capable of crossing the plasma membrane, 
cell-penetrating peptides are an   attractive tool for delivering 
nanoparticles into cells. Penetration of the plasma membrane 
by cell-penetrating peptides is not dependent on linkage 
with other molecules, and nanoparticles up to 200 nm in 
diameter can be transported across the plasma membrane 
by this method.29
Finally, biodistribution studies of the rhodamine-loaded 
nanoparticles were performed in mice to analyze their tissue 
selectivity, body clearance, and potential brain localization. 
Various rhodamine-loaded gelatin-siloxane nanoparticles 
were injected via the caudal vein using a rat model, and 
accumulation of the different gelatin-siloxane nanoparticles 
was then evaluated qualitatively and quantitatively using an 
in vivo imaging system. Figure 7 shows dynamic imaging 
of the nude mice, with strong fluorescence signals observed 
in the brain area of the mice treated with SynB-PEG-GS 
nanoparticles at various time points. However, there was 
no obvious fluorescence signal in the brain areas of mice 
treated with PEG-GS nanoparticles. These results sug-
gest that PEG-GS nanoparticles decorated with the SynB 
peptide have significant potential for brain targeting and 
delivery. Further, in order to confirm the amount of nano-
particles within brain tissue and other organs, the mice were 
sacrificed at 0.5, 2, 4, 6, 12, and 24 hours after injection. 
Their brains and livers were collected immediately, washed 
twice with physiological saline solution, and then visual-
ized using a Maestro in vivo imaging system. As shown in 
Figure 8, SynB-PEG-GS nanoparticle concentrations were 
significantly higher than those of PEG-GS nanoparticles at 
all time points (P , 0.01) in the brain area. However, unlike 
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localization in the brain, total fluorescent signals of PEG-GS 
nanoparticles were significantly higher than those of SynB-
PEG-GS nanoparticles (P , 0.01) in the liver area at the 
different time points. These results indicate that the modified 
SynB peptide could not only help PEG-GS nanoparticles to 
evade the reticuloendothelial system but also to cross the 
blood–brain barrier.
Conclusion
Improved delivery of nanoparticles to the brain was achieved 
by conjugating SynB peptide with PEG and gelatin-siloxane. 
We have demonstrated that SynB-PEG-GS nanoparticles 
have a good morphology and size distribution, and favorable 
cytotoxic properties. Moreover, SynB-PEG-GS nanopar-
ticles showed higher efficiency in uptake by brain capillary 
endothelial cells and ability to cross the blood–brain barrier. 
In addition, biodistribution studies of the different rhod-
amine-loaded nanoparticles demonstrated that the modified 
SynB peptide could not help PEG-GS nanoparticles to evade 
the reticuloendothelial system also cross the blood–brain 
barrier. We believe that SynB-PEG-GS nanoparticles hold 
great promise for efficient, noninvasive, and brain-targeting 
drug delivery.
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